Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors

Masayuki Hijioka, Tetsuhide Ito, Hisato Igarashi, Nao Fujimori, Lingaku Lee, Taichi Nakamura, Robert T. Jensen, Ryoichi Takayanagi

研究成果: ジャーナルへの寄稿記事

22 引用 (Scopus)

抄録

Although chromogranin A (CGA) is a useful marker for pancreatic neuroendocrine tumors (pNET) in the West, its usefulness in Japanese populations is unclear. To assess this, we evaluated the serum CGA levels in 189 patients with various pancreatic diseases, including proven pNET (n = 69), pancreatic cancer (PC) (n = 50), chronic pancreatitis (CP) (n = 50) and autoimmune pancreatitis (AIP) (n = 20), and 112 normal controls (controls) using an ELISA kit. The mean CGA level of patients with pNET was significantly higher than any of the other groups (407.8 ± 984.6 ng/mL [pNET] vs 91.8 ± 101.8 ng/mL [PC], 93.6 ± 57.5 ng/mL [CP], 69.9 ± 52.4 ng/mL [AIP] and 62.5 ± 48.3 ng/mL [controls]). Limiting the analysis to patients not using proton pump inhibitors (PPI), the CGA level of patients with PC or CP was not significantly different compared with the controls. Discriminant analysis revealed that the best cut-off value of CGA to distinguish patients with pNET from the controls was 78.7 ng/mL, with a sensitivity and specificity of 53.6% and 78.6%, respectively. In patients with pNET, significant factors associating with elevated CGA levels were tumor classification, tumor size, and the presence of liver metastases in univariate analysis as well as PPI use and the presence of liver metastases in multivariate analysis. We show that CGA is a useful marker for diagnosing pNET in Japanese populations and for distinguishing patients with pNET from patients with other pancreatic diseases. The increased use of CGA in Japan will likely be a helpful tool in managing these patients, as found in the West.

元の言語英語
ページ(範囲)1464-1471
ページ数8
ジャーナルCancer Science
105
発行部数11
DOI
出版物ステータス出版済み - 11 1 2014

Fingerprint

Chromogranin A
Neuroendocrine Tumors
Serum
Chronic Pancreatitis
Pancreatic Neoplasms
Pancreatic Diseases
Proton Pump Inhibitors
Pancreatitis
Neoplasm Metastasis
Liver
Discriminant Analysis
Population
Neoplasms
Japan
Multivariate Analysis
Enzyme-Linked Immunosorbent Assay
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Hijioka, M., Ito, T., Igarashi, H., Fujimori, N., Lee, L., Nakamura, T., ... Takayanagi, R. (2014). Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. Cancer Science, 105(11), 1464-1471. https://doi.org/10.1111/cas.12533

Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. / Hijioka, Masayuki; Ito, Tetsuhide; Igarashi, Hisato; Fujimori, Nao; Lee, Lingaku; Nakamura, Taichi; Jensen, Robert T.; Takayanagi, Ryoichi.

:: Cancer Science, 巻 105, 番号 11, 01.11.2014, p. 1464-1471.

研究成果: ジャーナルへの寄稿記事

Hijioka, M, Ito, T, Igarashi, H, Fujimori, N, Lee, L, Nakamura, T, Jensen, RT & Takayanagi, R 2014, 'Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors', Cancer Science, 巻. 105, 番号 11, pp. 1464-1471. https://doi.org/10.1111/cas.12533
Hijioka, Masayuki ; Ito, Tetsuhide ; Igarashi, Hisato ; Fujimori, Nao ; Lee, Lingaku ; Nakamura, Taichi ; Jensen, Robert T. ; Takayanagi, Ryoichi. / Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors. :: Cancer Science. 2014 ; 巻 105, 番号 11. pp. 1464-1471.
@article{951dbbad00b1454a80ca05a473f04631,
title = "Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors",
abstract = "Although chromogranin A (CGA) is a useful marker for pancreatic neuroendocrine tumors (pNET) in the West, its usefulness in Japanese populations is unclear. To assess this, we evaluated the serum CGA levels in 189 patients with various pancreatic diseases, including proven pNET (n = 69), pancreatic cancer (PC) (n = 50), chronic pancreatitis (CP) (n = 50) and autoimmune pancreatitis (AIP) (n = 20), and 112 normal controls (controls) using an ELISA kit. The mean CGA level of patients with pNET was significantly higher than any of the other groups (407.8 ± 984.6 ng/mL [pNET] vs 91.8 ± 101.8 ng/mL [PC], 93.6 ± 57.5 ng/mL [CP], 69.9 ± 52.4 ng/mL [AIP] and 62.5 ± 48.3 ng/mL [controls]). Limiting the analysis to patients not using proton pump inhibitors (PPI), the CGA level of patients with PC or CP was not significantly different compared with the controls. Discriminant analysis revealed that the best cut-off value of CGA to distinguish patients with pNET from the controls was 78.7 ng/mL, with a sensitivity and specificity of 53.6{\%} and 78.6{\%}, respectively. In patients with pNET, significant factors associating with elevated CGA levels were tumor classification, tumor size, and the presence of liver metastases in univariate analysis as well as PPI use and the presence of liver metastases in multivariate analysis. We show that CGA is a useful marker for diagnosing pNET in Japanese populations and for distinguishing patients with pNET from patients with other pancreatic diseases. The increased use of CGA in Japan will likely be a helpful tool in managing these patients, as found in the West.",
author = "Masayuki Hijioka and Tetsuhide Ito and Hisato Igarashi and Nao Fujimori and Lingaku Lee and Taichi Nakamura and Jensen, {Robert T.} and Ryoichi Takayanagi",
year = "2014",
month = "11",
day = "1",
doi = "10.1111/cas.12533",
language = "English",
volume = "105",
pages = "1464--1471",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors

AU - Hijioka, Masayuki

AU - Ito, Tetsuhide

AU - Igarashi, Hisato

AU - Fujimori, Nao

AU - Lee, Lingaku

AU - Nakamura, Taichi

AU - Jensen, Robert T.

AU - Takayanagi, Ryoichi

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Although chromogranin A (CGA) is a useful marker for pancreatic neuroendocrine tumors (pNET) in the West, its usefulness in Japanese populations is unclear. To assess this, we evaluated the serum CGA levels in 189 patients with various pancreatic diseases, including proven pNET (n = 69), pancreatic cancer (PC) (n = 50), chronic pancreatitis (CP) (n = 50) and autoimmune pancreatitis (AIP) (n = 20), and 112 normal controls (controls) using an ELISA kit. The mean CGA level of patients with pNET was significantly higher than any of the other groups (407.8 ± 984.6 ng/mL [pNET] vs 91.8 ± 101.8 ng/mL [PC], 93.6 ± 57.5 ng/mL [CP], 69.9 ± 52.4 ng/mL [AIP] and 62.5 ± 48.3 ng/mL [controls]). Limiting the analysis to patients not using proton pump inhibitors (PPI), the CGA level of patients with PC or CP was not significantly different compared with the controls. Discriminant analysis revealed that the best cut-off value of CGA to distinguish patients with pNET from the controls was 78.7 ng/mL, with a sensitivity and specificity of 53.6% and 78.6%, respectively. In patients with pNET, significant factors associating with elevated CGA levels were tumor classification, tumor size, and the presence of liver metastases in univariate analysis as well as PPI use and the presence of liver metastases in multivariate analysis. We show that CGA is a useful marker for diagnosing pNET in Japanese populations and for distinguishing patients with pNET from patients with other pancreatic diseases. The increased use of CGA in Japan will likely be a helpful tool in managing these patients, as found in the West.

AB - Although chromogranin A (CGA) is a useful marker for pancreatic neuroendocrine tumors (pNET) in the West, its usefulness in Japanese populations is unclear. To assess this, we evaluated the serum CGA levels in 189 patients with various pancreatic diseases, including proven pNET (n = 69), pancreatic cancer (PC) (n = 50), chronic pancreatitis (CP) (n = 50) and autoimmune pancreatitis (AIP) (n = 20), and 112 normal controls (controls) using an ELISA kit. The mean CGA level of patients with pNET was significantly higher than any of the other groups (407.8 ± 984.6 ng/mL [pNET] vs 91.8 ± 101.8 ng/mL [PC], 93.6 ± 57.5 ng/mL [CP], 69.9 ± 52.4 ng/mL [AIP] and 62.5 ± 48.3 ng/mL [controls]). Limiting the analysis to patients not using proton pump inhibitors (PPI), the CGA level of patients with PC or CP was not significantly different compared with the controls. Discriminant analysis revealed that the best cut-off value of CGA to distinguish patients with pNET from the controls was 78.7 ng/mL, with a sensitivity and specificity of 53.6% and 78.6%, respectively. In patients with pNET, significant factors associating with elevated CGA levels were tumor classification, tumor size, and the presence of liver metastases in univariate analysis as well as PPI use and the presence of liver metastases in multivariate analysis. We show that CGA is a useful marker for diagnosing pNET in Japanese populations and for distinguishing patients with pNET from patients with other pancreatic diseases. The increased use of CGA in Japan will likely be a helpful tool in managing these patients, as found in the West.

UR - http://www.scopus.com/inward/record.url?scp=84911432197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911432197&partnerID=8YFLogxK

U2 - 10.1111/cas.12533

DO - 10.1111/cas.12533

M3 - Article

C2 - 25220535

AN - SCOPUS:84911432197

VL - 105

SP - 1464

EP - 1471

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -